Page 269 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 269
Phenotyping assays for predicting DPD deficiency
29. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34.
30. NCI. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. https:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, 5 May 2017.
31. Leyva A, van Groeningen CJ, Kraal I, et al. Phase I and pharmacokinetic studies of high-dose
uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res. 1984;44(12 Pt 1):5928-5933.
32. Tonk ECM, Gurwitz D, Maitland-van der Zee AH, Janssens A. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association
studies. Pharmacogenomics J. 2017;17(4):386-392.
33. Hsiao H-H, Lin S-F. Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency.
Current Pharmacogenomics. 2007;5(1):31-38.
267
10
